Enliven Therapeutics (ELVN) Assets (2019 - 2026)
Enliven Therapeutics (ELVN) posted Assets of $464.9 million for Q1 2026, down 2.38% sequentially from $476.2 million in Q4 2025, and up 53.63% YoY from $302.6 million in Q1 2025.
Enliven Therapeutics (ELVN) Assets (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Assets for 8 years, with the latest figure at $464.9 million in Q1 2026.
- Quarterly Assets rose 53.63% year-over-year to $464.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $464.9 million (up 53.63% YoY) and the FY2025 annual result came in at $476.2 million, up 46.17% from the prior year.
- Assets fell to $464.9 million in Q1 2026 per ELVN's latest filing, from $476.2 million in the prior quarter.
- Over five years, Assets peaked at $503.9 million in Q2 2025 and troughed at $59.1 million in Q3 2022.
- A 5-year average of $292.1 million and a median of $302.9 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets slumped 44.78% in 2022, then surged 363.66% in 2023.
- Over 5 years, Assets stood at $83.3 million in 2022, then surged by 226.38% to $271.9 million in 2023, then grew by 19.82% to $325.8 million in 2024, then soared by 46.17% to $476.2 million in 2025, then declined by 2.38% to $464.9 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $464.9 million, $476.2 million, and $490.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 910.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 910.22 Mn |
| Mar 31, 2026 | 464.85 Mn |
| Dec 31, 2025 | 476.17 Mn |
| Sep 30, 2025 | 490.88 Mn |
| Jun 30, 2025 | 503.89 Mn |
| Mar 31, 2025 | 302.57 Mn |
| Dec 31, 2024 | 325.76 Mn |
| Sep 30, 2024 | 305.43 Mn |
| Jun 30, 2024 | 327.04 Mn |
| Mar 31, 2024 | 342.78 Mn |
| Dec 31, 2023 | 271.87 Mn |
| Sep 30, 2023 | 274.04 Mn |
| Jun 30, 2023 | 288.50 Mn |
| Mar 31, 2023 | 302.87 Mn |
| Dec 31, 2022 | 83.30 Mn |
| Sep 30, 2022 | 59.10 Mn |
| Jun 30, 2022 | 64.67 Mn |
| Mar 31, 2022 | 81.60 Mn |
| Dec 31, 2021 | 93.65 Mn |
| Sep 30, 2021 | 107.03 Mn |